Did Morgan Stanley's bond traders match the performance of rivals – or get beaten by them?
posted huge rebounds to fixed income trading revenue, it remains to be seen whether Morgan Stanley's smaller operations held their own.has tilted Morgan Stanley towards wealth management and overhauled its once-struggling bond trading division.
But the trading and advisory operations are still a crucial part of the company's business mix.due to an uncertain global economic outlook, a cull that hit technology and operations roles the hardest, people with knowledge of the matter said.Earlier this week, J.P. Morgan,
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Morgan Stanley has promoted 130 new managing directors for its 2020 class - Business InsiderThat's fewer new MD promotions than in recent years at the investment bank, which has been cutting costs and jobs in recent months.
Read more »
Morgan Stanley earnings, retail sales, manufacturing gauge: 3 things to watch for in the markets ThursdayWe'll get earnings from Morgan Stanley, retail sales and Philadelphia Federal Reserve manufacturing index results on Thursday.
Read more »
JP Morgan beats analysts' estimate for fourth-quarter profit on record Wall Street revenueJ.P. Morgan, the biggest U.S. bank by assets, is the first major lender to report earnings.
Read more »
Tesla shares fall after Morgan Stanley recommends dumping the stock. Here are the detailsMorgan Stanley downgraded the company to underweight and urged clients to wait for a better entry point to buy the stock.
Read more »
JP Morgan admits to `terrible customer experience' in response to discrimination allegationsA newspaper article about racial discrimination sent shock waves throughout J.P. Morgan, the biggest U.S. lender with 257,000 employees.
Read more »
Confusion and hype over 'digital health' overshadows J.P. Morgan health conferenceOther big topics at this week's J.P. Morgan Healthcare Conference in San Francisco included the lack of diversity at the executive ranks, drug pricing, big tech's march into the sector, and the missing patient voice.
Read more »